OncoSenX
Matt is a co-founder of OncoSenX and serves as CEO and Chairman. A serial entrepreneur with a background in computer security and immunology, Matt is also the founder and CEO of Oisín Biotechnoligies and former CEO of Immusoft, a biotech firm developing a breakthrough technology that will turn a patient's B cells into miniature drug factories. He’s a graduate of the University of Washington and a frequent speaker at the UW School of Business.
OncoSenX
OncoSenX is a late stage pre-clinical cancer company headquartered in Seattle, Washington. OncoSenX targets solid tumors based on transcriptional activity using a unique lipid nanoparticle and plasmid DNA.